177 related articles for article (PubMed ID: 27356987)
21. NSD1 PHD domains bind methylated H3K4 and H3K9 using interactions disrupted by point mutations in human sotos syndrome.
Pasillas MP; Shah M; Kamps MP
Hum Mutat; 2011 Mar; 32(3):292-8. PubMed ID: 21972110
[TBL] [Abstract][Full Text] [Related]
22. Nizp1 is a specific NUP98-NSD1 functional interactor that regulates NUP98-NSD1-dependent oncogenic programs.
Berardi A; Botrugno OA; Quilici G; Manteiga JMG; Bachi A; Tonon G; Musco G
FEBS J; 2023 Apr; 290(7):1782-1797. PubMed ID: 36271682
[TBL] [Abstract][Full Text] [Related]
23. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
[TBL] [Abstract][Full Text] [Related]
25. Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1.
Kudithipudi S; Lungu C; Rathert P; Happel N; Jeltsch A
Chem Biol; 2014 Feb; 21(2):226-37. PubMed ID: 24412544
[TBL] [Abstract][Full Text] [Related]
26. Dynamic behavior of the post-SET loop region of NSD1: Implications for histone binding and drug development.
Graham SE; Tweedy SE; Carlson HA
Protein Sci; 2016 May; 25(5):1021-9. PubMed ID: 26940890
[TBL] [Abstract][Full Text] [Related]
27. Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2.
Poulin MB; Schneck JL; Matico RE; Hou W; McDevitt PJ; Holbert M; Schramm VL
J Am Chem Soc; 2016 Jun; 138(21):6699-702. PubMed ID: 27183271
[TBL] [Abstract][Full Text] [Related]
28. Decreased serum dependence in the growth of NIH3T3 cells from the overexpression of human nuclear receptor-binding SET-domain-containing protein 1 (NSD1) or fission yeast su(var)3-9, enhancer-of-zeste, trithorax 2 (SET2).
Yamada-Okabe T; Matsumoto N
Cell Biochem Funct; 2008; 26(2):146-50. PubMed ID: 17437319
[TBL] [Abstract][Full Text] [Related]
29. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract][Full Text] [Related]
30. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Kim JY; Kee HJ; Choe NW; Kim SM; Eom GH; Baek HJ; Kook H; Kook H; Seo SB
Mol Cell Biol; 2008 Mar; 28(6):2023-34. PubMed ID: 18172012
[TBL] [Abstract][Full Text] [Related]
31. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
[TBL] [Abstract][Full Text] [Related]
32. Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches.
Carlino L; Astles PC; Ackroyd B; Ahmed A; Chan C; Collie GW; Dale IL; O'Donovan DH; Fawcett C; di Fruscia P; Gohlke A; Guo X; Hao-Ru Hsu J; Kaplan B; Milbradt AG; Northall S; Petrović D; Rivers EL; Underwood E; Webb A
J Med Chem; 2024 Jun; 67(11):8962-8987. PubMed ID: 38748070
[TBL] [Abstract][Full Text] [Related]
33. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
Poulin MB; Schneck JL; Matico RE; McDevitt PJ; Huddleston MJ; Hou W; Johnson NW; Thrall SH; Meek TD; Schramm VL
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1197-201. PubMed ID: 26787850
[TBL] [Abstract][Full Text] [Related]
34. NSD family proteins: Rising stars as therapeutic targets.
He L; Cao Y; Sun L
Cell Insight; 2024 Apr; 3(2):100151. PubMed ID: 38371593
[TBL] [Abstract][Full Text] [Related]
35. The catalytic domain of the histone methyltransferase NSD2/MMSET is required for the generation of B1 cells in mice.
Dobenecker MW; Marcello J; Becker A; Rudensky E; Bhanu NV; Carrol T; Garcia BA; Prinjha R; Yurchenko V; Tarakhovsky A
FEBS Lett; 2020 Oct; 594(20):3324-3337. PubMed ID: 32862441
[TBL] [Abstract][Full Text] [Related]
36. Identification of alternative transcripts of NSD1 gene in Sotos Syndrome patients and healthy subjects.
Conteduca G; Testa B; Baldo C; Arado A; Malacarne M; Candiano G; Garbarino A; Coviello DA; Cantoni C
Gene; 2023 Jan; 851():146970. PubMed ID: 36261088
[TBL] [Abstract][Full Text] [Related]
37. NSD2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract][Full Text] [Related]
38. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
39. The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence-associated epigenomic remodeling.
Tanaka H; Igata T; Etoh K; Koga T; Takebayashi SI; Nakao M
Aging Cell; 2020 Jul; 19(7):e13173. PubMed ID: 32573059
[TBL] [Abstract][Full Text] [Related]
40. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]